The study team created a murine lung tumor model driven by KrasG12D and compared tumors with intact Trp53 (K), single-allele Trp53 loss (KP+/-), and complete Trp53 loss (KP, from public datasets). Single-cell transcriptomic analysis of lungs burdened by tumors revealed a striking difference: the KP+/- genotype exhibited an expanded set of transcriptional states not observed in K or KP tumors. The authors reported that this expanded transcriptional plasticity is a defining feature of heterozygosity at the Trp53 locus in the context of KRAS-initiated lung tumors. This observation links gene-dosage at a canonical tumor suppressor locus directly to diversity in tumor cell phenotypes, a concept with implications for how tumors evolve under selective pressures.
The cohort showed that mice with intact Trp53 (K) and mice with single-allele Trp53 loss (KP+/-) lived longer than mice with complete Trp53 loss (KP). The authors noted that these murine survival patterns parallel clinical data: retention of a wild-type TP53 allele in human tumors has been associated with comparatively better outcomes than complete TP53 loss. The report did not include precise survival intervals or hazard ratios in the abstract; those details were not provided in the source summary.
Data indicated greater genomic instability in KP+/- mice relative to KP genotype tumors. The study team reported that KP+/- tumors displayed higher levels of copy-number alterations and associated genomic-profile changes. The authors interpreted this as evidence that partial loss of Trp53 regulates not only transcriptional plasticity but also the genomic architecture and evolutionary trajectory of tumor cells in this KRAS-driven model. The abstract did not specify the exact measures, thresholds, or the single-cell analytic pipelines used to quantify genomic instability; those methodological details were not included in the source text.
Investigators mapped murine KP+/- tumor signatures and copy-number profiles onto publicly available human NSCLC datasets. The report states that two KP+/-–derived signatures were associated with differential patient survival: one signature correlated with better survival, while another correlated with worse survival. Authors reported that KP+/- features therefore appear in human tumors and carry prognostic information. The summary did not list which human cohorts were interrogated, nor did it provide metrics such as effect sizes or statistical significance for those survival correlations; the source did not report those specifics in the abstract.
The authors concluded that Trp53 gene dosage governs phenotypic plasticity and evolutionary paths among K, KP+/-, and KP tumors in this KRAS-driven system. They suggested that TP53 heterozygosity in KRAS-mutant lung cancers creates a distinct genomic landscape that warrants consideration during therapeutic development. The abstract clarified that the single-allele retention of Trp53 confers longer survival in mice compared with full loss, consistent with clinical observations. The authors declared no competing interests and listed The University of Texas MD Anderson Cancer Center as funder. The preprint was posted on bioRxiv on October 14, 2026.
Limitations and specific unanswered questions remain explicit in the source: the abstract did not provide detailed methods for single-cell transcriptomic analyses, exact genomic instability metrics, cohort sizes, or the identities of the human NSCLC datasets used to map murine signatures. The summary also did not report therapeutic interventions, dosing regimens, or direct experimental tests of how the KP+/- transcriptional states respond to treatments. These gaps point to necessary follow-up: readers should consult the full manuscript for analytic pipelines, cohort statistics, and the precise human datasets and survival analyses used to derive the reported correlations.